Compound library / Fat Loss / GLP-1
Altimmune's dual GLP-1/glucagon receptor agonist in Phase 2 trials for obesity and MASH, notable for preserving lean mass better than some competitors in early data.
| Category | Fat Loss / GLP-1 |
|---|---|
| Typical route | Subcutaneous |
| Half-life | Supports weekly dosing |
| Common dose range | Trial dosing varies, not yet commercially approved |
| Typical cycle length | Not yet established outside trials |
BioHack Track models Pemvidutide at a half-life of 120 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Not commercially available outside clinical trials.
N/A — investigational.
Still investigational, not FDA-approved. Any access outside trials is grey-market with unverifiable sourcing/purity.
Track Pemvidutide in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Pemvidutide — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.